
Jupiter Neurosciences, Inc. (JUNS)
Last updated: 2026-10-24 16:38:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Jupiter Neurosciences, Inc. (JUNS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.99, with a market capitalization of $3.40M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.25 to $135.75. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$3.40M | |
$2.58 | |
$1,463.25 | |
$2.25 | |
$2.58 | |
19.24K | |
919.54K | |
-- | |
$135.75 | |
$2.25 | |
-- | |
-- |
Jupiter Neurosciences, Inc. (JUNS) Latest Closing Stock Price
Jupiter Neurosciences, Inc. (JUNS) last closed at $2.58 as of 2026-10-23 23:31:00, unchanged from the previous close of $2.58.
During the latest regular trading session, JUNS traded between $2.25 and $1,463.25, with a volume of 19.24K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Jupiter Neurosciences, Inc. (JUNS) 7-Day Stock Price Change
Over the past seven days, Jupiter Neurosciences, Inc. (JUNS) moved from $3.14 to $2.99, representing a decline of 4.78% ($0.15).
The stock traded between $2.52 and $3.27 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 16.03 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
JUNS 52-Week Price Position
Position in Range: 0.6%
JUNS is currently trading at $2.99, placing it 0.6% of the way from its 52-week low of $2.25 to its 52-week high of $135.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Jupiter Neurosciences, Inc. (JUNS)?
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
Jupiter Neurosciences, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Jupiter Neurosciences, Inc. (JUNS) Stock on MEXC
Eligible investors can buy real shares of Jupiter Neurosciences, Inc. (JUNS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Jupiter Neurosciences, Inc. (JUNS) stock price today?
2.Is JUNS stock going up or down today?
3.What is JUNS pre-market price?
4.What is JUNS after-hours price?
5.Is JUNS stock trading now?
6.Where does JUNS sit relative to its 52-week high and low?
7.What sector is Jupiter Neurosciences, Inc. in?
8.What is Jupiter Neurosciences, Inc.'s market capitalization and where is it listed?
9.How is JUNS valued in terms of P/E ratio and EPS?
10.Does Jupiter Neurosciences, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
JUNS Stock Calculator
Estimate the value between JUNS shares and USD.
JUNS Shares to USD
1.00 JUNS shares = 2.99 USD
Calculations are estimates based on the latest available price and are for reference only.


